Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics

Abstract

The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

1 . A method of treating a subject, comprising the step of administering to the subject a composition that includes an isolated nucleic acid encoding a  S. pneumoniae  polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 5225, wherein the polypeptide elicits an immune response in the subject.  
     
     
         2 . The method of  claim 1 , wherein the isolated nucleic acid administered to the subject is a component of a vector.  
     
     
         3 . The method of  claim 2 , wherein the vector is a component of a cell.  
     
     
         4 . A method of treating a subject, comprising the step of administering to the subject a composition that includes an isolated nucleic acid as set forth in SEQ ID NO: 2564, wherein the isolated nucleic acid encodes a polypeptide that elicits an immune response in the subject.  
     
     
         5 . The method of  claim 4 , wherein the isolated nucleic acid administered to the subject is a component of a vector.  
     
     
         6 . The method of  claim 5 , wherein the vector is a component of a cell.  
     
     
         7 . A method of treating a subject, comprising the step of administering to the subject a composition that includes an isolated nucleic acid selected from the group consisting of: 
 a) SEQ ID NO: 2564;    b) a nucleic acid fully complementary to SEQ ID NO: 2564;    c) a nucleic acid having at least 99% identity to SEQ ID NO: 2564;    d) a nucleic acid fully complementary to a nucleic acid having at least 99% identity to SEQ ID NO: 2564; and    e) an RNA of a), b), c) or d) wherein U is substituted for T, wherein the isolated nucleic acid encodes a polypeptide that elicits an immune response in the subject.    
     
     
         8 . A method of treating a subject, comprising the step of administering to the subject a composition that includes an isolated nucleic acid encoding a  S. pneumoniae  polypeptide selected from the group consisting of: 
 (a) SEQ ID NO: 5225; and    (b) a polypeptide having at least 99% identity to SEQ ID NO: 5225, wherein administration of the polypeptide elicits an immune response in the subject.    
     
     
         9 . A method of treating a subject, comprising the step of administering to the subject a composition that includes an isolated nucleic acid encoding a  S. pneumoniae  polypeptide having at least 99% identity to SEQ ID NO: 5225, wherein the polypeptide elicits an immune response in the subject.  
     
     
         10 . A method of treating a  S. pneumoniae  infection in a subject, comprising the step of administering to a subject having an  S. pneumoniae  infection a composition that includes an isolated nucleic acid encoding a  S. pneumoniae  polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 5225.  
     
     
         11 . The method of  claim 10 , wherein the isolated nucleic acid administered to the subject is a component of a vector.  
     
     
         12 . The method of  claim 11 , wherein the vector is a component of a cell.  
     
     
         13 . A method of treating a  S. pneumoniae  infection in a subject, comprising the step of administering to a subject having an  S. pneumoniae  infection a composition that includes an isolated nucleic acid as set forth in SEQ ID NO: 2564.  
     
     
         14 . The method of  claim 13 , wherein the isolated nucleic acid administered to the subject is a component of a vector.  
     
     
         15 . The method of  claim 14 , wherein the vector is a component of a cell.  
     
     
         16 . A method of treating a  S. pneumoniae  infection in a subject, comprising the step of administering to a subject having an  S. pneumoniae  infection a composition that includes an isolated nucleic acid selected from the group consisting of: 
 a) SEQ ID NO: 2564;    b) a nucleic acid fully complementary to SEQ ID NO: 2564;    c) a nucleic acid having at least 99% identity to SEQ ID NO: 2564;    d) a nucleic acid fully complementary to a nucleic acid having at least 99% identity to SEQ ID NO: 2564; and    e) an RNA of a), b), c) or d) wherein U is substituted for T.    
     
     
         17 . A method of treating a  S. pneumoniae  infection in a subject, comprising the step of administering to a subject having an  S. pneumoniae  infection a composition that includes an isolated nucleic acid encoding a  S. pneumoniae  polypeptide selected from the group consisting of: 
 (a) SEQ ID NO: 5225 and    (b) a polypeptide having at least 99% identity to SEQ ID NO: 5225.    
     
     
         18 . A method of treating a  S. pneumoniae  infection in a subject, comprising the step of administering to a subject having an  S. pneumoniae  infection a composition that includes an isolated nucleic acid encoding a  S. pneumoniae  polypeptide having at least 99% identity to SEQ ID NO: 5225.  
     
     
         19 . A method of treating a subject, comprising the step of administering to the subject a composition that includes an isolated nucleic acid encoding a  S. pneumoniae  polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 5225, wherein the polypeptide provides protective immunity against an infection by  S. pneumoniae.    
     
     
         20 . The method of  claim 19 , wherein the isolated nucleic acid administered to the subject is a component of a vector.  
     
     
         21 . The method of  claim 20 , wherein the vector is a component of a cell.  
     
     
         22 . A method of treating a subject, comprising the step of administering to the subject a composition that includes an isolated nucleic acid as set forth in SEQ ID NO: 2564, wherein the isolated nucleic acid encodes a polypeptide that provides protective immunity against an infection by  S. pneumoniae.    
     
     
         23 . The method of  claim 22 , wherein the isolated nucleic acid administered to the subject is a component of a vector.  
     
     
         24 . The method of  claim 23 , wherein the vector is a component of a cell.  
     
     
         25 . A method of treating a subject, comprising the step of administering to the subject a composition that includes an isolated nucleic acid selected from the group consisting of: 
 a) SEQ ID NO: 2564;    b) a nucleic acid fully complementary to SEQ ID NO: 2564;    c) a nucleic acid having at least 99% identity to SEQ ID NO: 2564;    d) a nucleic acid fully complementary to a nucleic acid having at least 99% identity to SEQ ID NO: 2564; and    e) an RNA of a), b), c) or d) wherein U is substituted for T,    wherein the isolated nucleic acid encodes a polypeptide that provides protective immunity against an infection by  S. pneumoniae.      
     
     
         26 . A method of treating a subject, comprising the step of administering to the subject a composition that includes an isolated nucleic acid encoding a  S. pneumoniae  polypeptide selected from the group consisting of: 
 (a) SEQ ID NO: 5225; and    (b) a polypeptide having at least 99% identity to SEQ ID NO: 5225, wherein administration of the polypeptide provides protective immunity against an infection by  S. pneumoniae.      
     
     
         27 . A method of treating a subject, comprising the step of administering to the subject a composition that includes an isolated nucleic acid encoding a  S. pneumoniae  polypeptide having at least 99% identity to SEQ ID NO: 5225, wherein the polypeptide provides protective immunity against an infection by  S. pneumoniae.